November 8, 2024
CORRECTION – 23andMe to Report Q2 FY2025 Financial Results
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — An earlier release under the same headline should have noted 23andMe Holding…
Pharmaceuticals, Biotechnology and Life Sciences
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — An earlier release under the same headline should have noted 23andMe Holding…
World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific DiscoveriesFREMONT, Calif., Nov. 07,…
November 7, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical…
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and…
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today…
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its…
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing…
Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended…
– Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025.…
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and…